PATTIES FOODS (PH4) - Total Liabilities
Based on the latest financial reports, PATTIES FOODS (PH4) has total liabilities worth €741.60 Million EUR (≈ $867.01 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. For the complete balance sheet picture, see balance sheet size of PATTIES FOODS.
PATTIES FOODS - Total Liabilities Trend (2020–2025)
This chart illustrates how PATTIES FOODS's total liabilities have evolved over time, based on quarterly financial data. See PH4 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
PATTIES FOODS Competitors by Total Liabilities
The table below lists competitors of PATTIES FOODS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Direcional Engenharia S.A.
SA:DIRR3
|
Brazil | R$9.70 Billion |
|
LuxExperience B.V.
NYSE:LUXE
|
USA | $826.13 Million |
|
Ye Chiu Metal Recycling China Ltd
SHG:601388
|
China | CN¥1.56 Billion |
|
Cyient Limited
NSE:CYIENT
|
India | Rs21.61 Billion |
|
BlackRock Health Sciences Trust II
NYSE:BMEZ
|
USA | $6.03 Million |
|
Total Gabon
F:RZW
|
Germany | €1.30 Billion |
|
Beijing SL Pharmaceutical Co Ltd
SHE:002038
|
China | CN¥735.46 Million |
|
Instalco Intressenter AB
ST:INSTAL
|
Sweden | Skr6.87 Billion |
Liability Composition Analysis (2020–2025)
This chart breaks down PATTIES FOODS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. Check PATTIES FOODS asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PATTIES FOODS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PATTIES FOODS (2020–2025)
The table below shows the annual total liabilities of PATTIES FOODS from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €741.60 Million ≈ $867.01 Million |
-27.97% |
| 2024-12-31 | €1.03 Billion ≈ $1.20 Billion |
-14.57% |
| 2023-12-31 | €1.21 Billion ≈ $1.41 Billion |
+1.35% |
| 2022-12-31 | €1.19 Billion ≈ $1.39 Billion |
+11.71% |
| 2021-12-31 | €1.06 Billion ≈ $1.24 Billion |
+31.69% |
| 2020-12-31 | €808.29 Million ≈ $944.98 Million |
-- |
About PATTIES FOODS
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junctio… Read more